ATE378601T1 - Diagnostischer test für menschlisches matrix gla- protein und seine verwendung als biomarker - Google Patents

Diagnostischer test für menschlisches matrix gla- protein und seine verwendung als biomarker

Info

Publication number
ATE378601T1
ATE378601T1 AT00954427T AT00954427T ATE378601T1 AT E378601 T1 ATE378601 T1 AT E378601T1 AT 00954427 T AT00954427 T AT 00954427T AT 00954427 T AT00954427 T AT 00954427T AT E378601 T1 ATE378601 T1 AT E378601T1
Authority
AT
Austria
Prior art keywords
protein
biomarker
matrix gla
diagnostic test
human matrix
Prior art date
Application number
AT00954427T
Other languages
English (en)
Inventor
Cees Vermeer
Original Assignee
Cardiovascular Res Inst Of Maa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiovascular Res Inst Of Maa filed Critical Cardiovascular Res Inst Of Maa
Application granted granted Critical
Publication of ATE378601T1 publication Critical patent/ATE378601T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/971Capture of complex after antigen-antibody reaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/972Modified antibody, e.g. hybrid, bifunctional
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00954427T 1999-07-04 2000-07-02 Diagnostischer test für menschlisches matrix gla- protein und seine verwendung als biomarker ATE378601T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202176 1999-07-04
EP00106409 2000-03-23

Publications (1)

Publication Number Publication Date
ATE378601T1 true ATE378601T1 (de) 2007-11-15

Family

ID=26070721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00954427T ATE378601T1 (de) 1999-07-04 2000-07-02 Diagnostischer test für menschlisches matrix gla- protein und seine verwendung als biomarker

Country Status (7)

Country Link
US (1) US6746847B1 (de)
EP (1) EP1190259B1 (de)
AT (1) ATE378601T1 (de)
AU (1) AU6688700A (de)
DE (1) DE60037115T2 (de)
ES (1) ES2296634T3 (de)
WO (1) WO2001002863A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700296B2 (en) 1999-07-04 2010-04-20 Mgp Diagnostics As Diagnostic assay for human Matrix Gla-protein and its use as a biomarker
US20070009955A1 (en) * 2002-07-08 2007-01-11 Lydie Bougueleret Secreted polypeptide species associated with cardiovascular disorders
EP2671574A1 (de) 2012-06-04 2013-12-11 VitaK B.V. Verwendung von Vitamin K zur Verringerung des Allotransplantatversagens und Patientensterblichkeit nach Organtransplantation
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016131993A2 (en) 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function
CA3119816A1 (en) * 2018-11-15 2020-05-22 Assistance Publique - Hopitaux De Paris Method for diagnosis and treating peripheral neuropathies
EP4132488A1 (de) 2020-04-09 2023-02-15 Emphysema Solutions BV Verwendung von vitamin k zur vorbeugung oder bekämpfung der covid-19-krankheit und diagnostischer test zur schätzung des risikos der entwicklung einer schweren krankheit oder sterblichkeit durch covid-19
NL2030584B1 (en) 2022-01-17 2023-07-27 Emphysema Solutions Bv Use of vitamin K in preventing or counteracting vaccine-related adverse events, symptoms, morbidity and/or mortality after vaccination against COVID-19 or another coronavirus

Also Published As

Publication number Publication date
EP1190259A1 (de) 2002-03-27
EP1190259B1 (de) 2007-11-14
DE60037115D1 (de) 2007-12-27
US6746847B1 (en) 2004-06-08
WO2001002863A1 (en) 2001-01-11
AU6688700A (en) 2001-01-22
DE60037115T2 (de) 2008-09-18
ES2296634T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
JP4236629B2 (ja) NT−proBNPを測定するためのサンドイッチ分析試験
US20070166776A1 (en) Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample
DK1232392T3 (da) Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring
PT838680E (pt) Determinacao de antigenios complexados especificos da prostata
JP2002532686A5 (de)
US6764825B1 (en) Methods and device for detecting prostate specific antigen (PSA)
KR910021585A (ko) 알쯔하이머병의 진단 분석법
JP3055789B2 (ja) 骨由来アルカリホスファターゼの検定法
Hidayat et al. Enzyme linked immunosorbent assay (ELISA) technique guideline
DE602005025559D1 (de) Diagnostischer Test für menschliches matrix Gla-Protein und seine Verwendung als Biomarker
JP7503505B2 (ja) 自己抗体の直接イムノアッセイ測定法
KR19980703302A (ko) 글루타치온 s-트랜스퍼라제의 하나 또는 그 이상의 아이소엔자임 검출에 기초한 장기 상태 평가를 위한 쾌속 검정법
ATE378601T1 (de) Diagnostischer test für menschlisches matrix gla- protein und seine verwendung als biomarker
Kamel et al. Development of new lateral-flow immunochromatographic strip using colloidal gold and mesoporous silica nanoparticles for rapid diagnosis of active schistosomiasis
KR20130081952A (ko) 암 진단용 바이오마커 및 이를 이용한 암세포 분리 방법
ATE78601T1 (de) Test fuer menschlichen brustkrebs.
CN105445471B (zh) 心血管疾病标记物palm及利用其的心血管疾病诊断方法
DE59602091D1 (de) Verwendung von polyklonalen humanen anti-htg-autoantikörpern als reagenz für die klinische diagnostik von schilddrüsen-autoimmunerkrankungen sowie reagenziensatz für eine bestimmung von anti-htg-autoantikörpern in patientenseren
EP0623214A1 (de) Bestimmung von haptenen
CN208537565U (zh) C-反应蛋白、血清淀粉样蛋白a免疫层析定量联合检测试纸条
CA2445102A1 (en) Method and means for detecting gluten-induced diseases
RU2227297C2 (ru) Моноклональные антитела против s100
JPH05113443A (ja) 酵素免疫測定方法
DE69811157T2 (de) Immunoassay zur Bestimmung von PSA-ACT
ITMI942238A1 (it) Anticorpi naturali contro proteine allogeniche e xenogeniche e metodi per la loro determinazione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1190259

Country of ref document: EP